Back to top
more

Corcept Therapeutics (CORT)

(Real Time Quote from BATS)

$34.06 USD

34.06
257,529

+0.18 (0.53%)

Updated Jul 22, 2024 12:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Options Traders Expect Huge Moves in Corcept (CORT) Stock

by Zacks Equity Research

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

by Zacks Equity Research

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

Corcept Therapeutics (CORT) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 15.79% and 5.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Corcept (CORT) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Corcept (CORT) Up 15.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2

by Zacks Equity Research

Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.

Corcept Therapeutics (CORT) Q2 Earnings Beat Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept Therapeutics (CORT) Q1 Earnings Top Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.

Corcept (CORT) Down 6.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.

Options Traders Expect Huge Moves in Corcept (CORT) Stock

by Zacks Equity Research

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Corcept (CORT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Corcept (CORT) Up 13.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept Initiates Phase III Study for Cushing's Syndrome

by Zacks Equity Research

Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.

Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates

by Zacks Equity Research

Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.

Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

    Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

    by Zacks Equity Research

    Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

      Corcept Therapeutics (CORT) Misses Q2 Earnings and Revenue Estimates

      by Zacks Equity Research

      Corcept (CORT) delivered earnings and revenue surprises of -16.67% and -9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock

        by Zacks Equity Research

        Investors in Corcept Therapeutics (CORT) need to pay close attention to the stock based on moves in the options market lately.

          Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?

          by Zacks Equity Research

          Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.